Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DI6EL3
|
|||
| Drug Name |
FB-101
|
|||
| Synonyms |
NULL
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 1 | [1] | |
| Company |
1ST Biotherapeutics, Inc.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H23F2N3O2
|
|||
| Canonical SMILES |
C1CCCN(CC1)C2=C(C(=C3CC(=CN(C3=C2F)C4CC4)C(=O)O)N)F
|
|||
| InChI |
InChI=1S/C19H23F2N3O2/c20-14-16(22)13-9-11(19(25)26)10-24(12-5-6-12)17(13)15(21)18(14)23-7-3-1-2-4-8-23/h10,12H,1-9,22H2,(H,25,26)
|
|||
| InChIKey |
XIADACXCBGCKCI-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04165837) A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.